SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote wound repair and prevent scarring of dermal wounds.  Our lead product, JVS-100 is a clinically tested product that encodes Stromal cell-Derived Factor-1 (SDF-1).  SDF-1 is produced by the body in response to tissue injury and activates natural repair processes to prevent cell death and recruit stem cells to the damaged organ.

        SironRX has a double-blind, placebo-controlled, randomized clinical trial underway evaluating the efficacy and safety of JVS-100 treatment in 48 patients that have undergone open-chest surgery. We are evaluating the effects of JVS-100 to accelerate wound repair and reduce scar formation. Previous clinical studies with JVS-100 have demonstrated the drug is well tolerated and safe.